Table 3.
Number of stage IIB or higher cancers by mode of detection*
| Prevalent cancers stage IIB or higher, no. |
Screen detected, no. |
Clinically detected, no. |
Total, no. |
|||||
|---|---|---|---|---|---|---|---|---|
| Risk group | Personalized | Annual | Personalized | Annual | Personalized | Annual | Personalized | Annual |
| Every 6 months | 2.3 | 2.3 | 5.1 | 3.9 | 1.5 | 2.1 | 6.5 | 6.0 |
| Annual | 7.1 | 7.1 | 12.0 | 12.0 | 6.7 | 6.6 | 18.7 | 18.6 |
| Biennial | 5.4 | 5.4 | 5.0 | 9.2 | 7.1 | 5.1 | 12.1 | 14.3 |
| No screening at this time | 1.8 | 1.8 | 2.1 | 3.1 | 2.9 | 1.7 | 5.0 | 4.9 |
| All risk groups | 16.6 | 16.6 | 24.2 | 28.2 | 18.1 | 15.5 | 42.3 | 43.7 |
*The table shows number of expected stage IIB or higher cancers in the Women Informed to Screen Depending on Measures of Risk (WISDOM) trial, by mode of detection, risk strata, and analysis approach. The results are based on the simulation model and are averaged across 5000 simulations.